PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Theriva Biologics, Inc.

USPTO PatentsView assignee record - 11 granted patents across 6 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Y (ENZYMES).

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Theriva ranks #25,400 of 50,000 tracked US assignees by granted-patent volume, with 11 patents across 6 technology areas.

#25,400
of 50,000 US assignees by volume
Top 23%
by Innovation Score (45.7/100)
14.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R25400 · US Corporation #25,400 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 11 grants
  • MID-PACK #25,400/50,000
  • PHOTO-FINISH The Swatch Group Man…
  • CPC-NARROW C12Y · 6 areas
  • INNOV-PAR 45.7/100
  • CLAIMS-RICH 14.1 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2023–2025 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: The Swatch Group Management Services Ag (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Theriva

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Theriva's Innovation Score is 45.7/100 (top 23% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Theriva's grants concentrate

Theriva Biologics, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C12Y (ENZYMES). Peak complete grant year is 2024 (6 grants) versus a trough of 3 in 2023. By volume, Theriva sits between The Swatch Group Management Services Ag and Threatstop, Inc..

Theriva's three-year grant acceleration

Theriva Biologics, Inc. shows 9 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Theriva's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Theriva holds 11 patents at rank #25,401, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Theriva

By rank, the assignees closest to #25,401 in granted patent volume.

Leaders in C12Y (Enzymes)

Other assignees with the most granted patents in Theriva's primary technology class.

Theriva's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 23% higher than 77% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

1234567 202320242025 2
USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table
Theriva Biologics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2023 3 27.3%
2024 6 54.5%
2025partial year 2 18.2%

Which technologies does Theriva Biologics, Inc. patent most?

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#25,400

of 50,000 tracked assignees

Innovation Score

45.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.